Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 05 2023
Historique:
revised: 22 11 2022
received: 28 09 2022
accepted: 16 12 2022
pubmed: 25 1 2023
medline: 15 3 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

Extending screening intervals in ongoing cancer screening programmes can lead to challenging year-on-year variations in the number of screening tests. We explored how such variation could be diminished with a managed transition to the extended interval. We defined three extension scenarios: immediate extension for the entire target population; stepped transition by birth cohort; and gradual transition by reducing the number of available screening appointments. These were compared to a situation in which the interval remains unchanged in a demographic model covering a 15-year period. The model was populated with observed parameters from England, a real-world setting recommending cervical screening with 3-year intervals at age 25-49 and 5-year intervals at age 50-64. Informed by typical changes currently considered by several European programmes including the programme in England, we explored the effect on screening test numbers of an extension of the 3-year interval to 5 years for women younger than 50. All three extension scenarios resulted in similar cumulative numbers of screening tests, which were about 30% lower compared to a situation in which the interval would remain unchanged. However, the year-on-year variation in the number of screening tests varied between the scenarios. This variation was around 4-fold for the immediate scenario. In the stepped scenario, the yearly numbers could differ by around 20%, whereas in the gradual scenario they were virtually constant. A managed interval extension, transitioning different groups of the target population at different times, can substantially reduce the yearly variation in screening workload without increasing the total number of screening tests in the long term.

Identifiants

pubmed: 36691808
doi: 10.1002/ijc.34441
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2061-2068

Subventions

Organisme : Cancer Research UK
ID : 25356
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 27047
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8162/A25356
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Br J Cancer. 2022 Jul;127(2):278-287
pubmed: 35347326
BMJ. 2022 May 31;377:e068776
pubmed: 35640960
BJOG. 2021 Jun;128(7):1226-1235
pubmed: 33247993
Health Policy. 2018 Nov;122(11):1206-1211
pubmed: 30170757
BMC Health Serv Res. 2016 Apr 26;16:147
pubmed: 27112193
N Engl J Med. 2020 Oct 1;383(14):1340-1348
pubmed: 32997908
Clin Microbiol Infect. 2020 May;26(5):579-583
pubmed: 31539637
Lancet. 2021 Dec 4;398(10316):2084-2092
pubmed: 34741816
Int J Cancer. 2018 Feb 15;142(4):709-718
pubmed: 29023748
Acta Dermatovenerol Alp Pannonica Adriat. 2021 Mar;30(1):21-26
pubmed: 33765753
J Med Screen. 2021 Sep;28(3):325-332
pubmed: 32862772
Ann Intern Med. 2018 Jan 2;168(1):20-29
pubmed: 29181509
Int J Cancer. 2023 May 15;152(10):2061-2068
pubmed: 36691808
Prev Med. 2021 Oct;151:106623
pubmed: 34029578
BMJ. 2019 Apr 3;365:l1161
pubmed: 30944092
BMJ. 2009 Jul 28;339:b2968
pubmed: 19638651
Lancet Public Health. 2021 Jul;6(7):e522-e527
pubmed: 33939965
BMJ. 2019 Feb 6;364:l240
pubmed: 30728133
BJOG. 2022 Jul;129(8):1278-1288
pubmed: 34913243

Auteurs

Francesca Pesola (F)

Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Matejka Rebolj (M)

Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Peter Sasieni (P)

Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH